Miglustat in Niemann-Pick Type C Disease

NCT00517153 | Completed Phase 2

• 1 other identifier: OGT-918-007
• Study Type: interventional
• Target: 29
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a phase II randomized controlled study of miglustat in adult and juvenile patients with Niemann-Pick Type C disease. Up to 42 patients will be randomised in a 2:1 ratio to either treatment with miglustat or to a non-treatment group. Both groups will follow an identical visit schedule.

Conditions

Niemann-Pick Type C Disease

Keywords

Zavesca; miglustat; Niemann-Pick Type C; Actelion

Outcome Measures

Primary Outcomes (1)

• The primary endpoints will be two parameters - Horizontal Saccadic α and Horizontal Saccadic β - which are estimated for each patient from their saccadic eye movement data

  Baseline to Month 12

Secondary Outcomes (1)

• Highest amplitude for which a velocity measurement is obtained

  Baseline to Month 12

Study Arms (2)

1

EXPERIMENTAL

OGT-918 - Zavesca (miglustat)

Drug: miglustat

2

NO INTERVENTION

Standard treatment

Interventions

miglustat DRUG

Patients aged 12 years or more randomised to the treatment group will receive 200 mg OGT 918 three times daily initially for twelve months. An additional sub-study of up to 12 patients aged under 12 years will receive a lower dose of OGT 918 according to their BSA

Also known as: Zavesca

1

Eligibility Criteria

• Age: 4 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with Niemann-Pick Type C disease confirmed by abnormal cholesterol esterification and abnormal filipin staining.
• Patients who can ingest a capsule.
• Patients who are above the age of four (4) years of age.

You may not qualify if:

• Patients younger than 18 years who are unable to give informed assent and/or whose legal guardian is unable to provide informed consent.
• Patients aged 18 and over who cannot provide informed consent and/or whose legal guardian is unable to provide witnessed informed consent.
• Sexually active and fertile patients who do not agree to use adequate contraception throughout the study and for three months after cessation of OGT 918 treatment.
• Patients who cannot tolerate the study procedures or who are unable to travel to the study center as required by this protocol.
• Patients currently undergoing therapy with other investigational agents or patients taking drugs or food supplements which may interfere with gastrointestinal absorption or motility.
• Patients suffering from clinically significant diarrhea (\>3 liquid stools per day for \>7 days) without definable cause within 3 months of Screening Visit, or who have a history of significant gastrointestinal disorders.
• Patients with an intercurrent medical condition that would render them unsuitable for the study e.g. HIV, hepatitis infection.
• Patients who in the opinion of the Investigator (for whatever reason) are thought to be unsuitable for the study.
• Patients with an adjusted Creatinine Clearance of less than 70 ml/min/1.73m2 (CrCl \<70).
• Patients younger than four (4) years of age.

Sponsors & Collaborators

• Actelion: lead

MeSH Terms

Conditions

Niemann-Pick Disease, Type C

Interventions

miglustat

Condition Hierarchy (Ancestors)

Niemann-Pick Diseases; Sphingolipidoses; Lysosomal Storage Diseases, Nervous System; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Histiocytosis, Non-Langerhans-Cell; Histiocytosis; Lymphatic Diseases; Hemic and Lymphatic Diseases; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Lipidoses; Lipid Metabolism, Inborn Errors; Lysosomal Storage Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases; Lipid Metabolism Disorders

Study Officials

• Claudia Chiriboga, Assoc. Prof. MD

  Columbia University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: August 15, 2007
• First Posted: August 16, 2007
• Study Start: January 1, 2002
• Primary Completion: September 1, 2006
• Study Completion: January 1, 2008
• Last Updated: February 4, 2025

Record last verified: 2025-01